A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552 · ADAPT SERON Phase 3Active, not recruiting
- Lead sponsor
- argenx (Industry)
- Enrollment
- 119 (actual)
- Start date
- 16 Apr 2024
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 1 Jun 2028
- Last update posted
- 10 Aug 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- Efgartigimod IV Biological
- Placebo IV Other
Conditions and primary outcome
- Generalized Myasthenia Gravis
- gMG
- Myasthenia Gravis, Generalized
- Myasthenia Gravis
Primary outcome
MG-ADL Total Score Change From Baseline (Up to 29 days in part A)
Posted results on ClinicalTrials.gov
Source: ClinicalTrials.gov results for NCT06298552 (opens in a new tab)· Licence: public-domain
First posted · Last update posted · Imported from ClinicalTrials.gov download 2026-10-25
Primary outcomes with a statistical analysis
No primary outcome with a statistical analysis is posted for this study.
Serious adverse events
Time frame: Available data included for Part A (up to 8 weeks).
| Group | Affected | At risk |
|---|---|---|
| Efgartigimod IV | 3 | 58 |
| Placebo | 1 | 61 |
Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06298552.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06298552 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.